In a new report in 2017, Tsang et al. [90] found that tumor-targeting peptides (iRGD and cRGD) coupled to U1 adaptors with fluorescence presented targeted tumor localization and highly potent anticancer efficacy (>90%) by targeting two oncogenes (KRAS and MYC) in pancreatic cancer in vivo. The gene discussed is KRAS; the disease is pancreatic neoplasm.